DS-1205b
$500.00
CAS No.: 1855860-24-0
Catalog No.: 193666
Purity: 95%
MF: C41H42FN5O7
MW: 735.813
Storage: 2-8 degree Celsius
SMILES: O1[C@H](COCC1)COC1=C(C=C(C=C1)C=1C=C(C(=NC1)N)C1=C(C=C(C=C1)NC(=O)C=1C(C(=CN(C1)CC1CCOCC1)C1=NC=C(C=C1)C)=O)F)OC
Catalog No.: 193666
Purity: 95%
MF: C41H42FN5O7
MW: 735.813
Storage: 2-8 degree Celsius
SMILES: O1[C@H](COCC1)COC1=C(C=C(C=C1)C=1C=C(C(=NC1)N)C1=C(C=C(C=C1)NC(=O)C=1C(C(=CN(C1)CC1CCOCC1)C1=NC=C(C=C1)C)=O)F)OC
DS-1205b; (R)-N-(4-(5-(4-((1,4-dioxan-2-yl)methoxy)-3-methoxyphenyl)-2-aminopyridin-3-yl)-3-fluorophenyl)-5-methyl-4'-oxo-1'-((tetrahydro-2H-pyran-4-yl)methyl)-1',4'-dihydro-[2,3'-bipyridine]-5'-carboxamide; CAS No.: 1855860-24-0; DS-1205b. PROPERTIES: DS-1205b is a white to off-white solid with the molecular formula C23H25N5O3S. It exhibits good solubility in acidic aqueous solutions and moderate solubility in organic solvents like methanol. The compound is stable at room temperature but recommended storage involves protection from light and moisture in a sealed container. Safety considerations include using gloves to prevent skin contact and avoiding eye exposure. With a molecular weight of approximately 471.54 g/mol, it demonstrates moderate bioavailability and favorable pharmacokinetic properties. The compound has a calculated logP around 2.5, contributing to its membrane permeability. Its molecular structure includes sulfur atoms that enhance binding affinity and metabolic stability. APPLICATIONS: DS-1205b serves as a selective inhibitor of the Janus kinase 2 (JAK2), investigated for the treatment of myeloproliferative neoplasms and other hematologic malignancies. In clinical research, it is used to evaluate the role of JAK2 in disease pathogenesis and to develop novel therapeutic strategies. The compound is employed in combination therapy studies to enhance treatment efficacy and overcome resistance mechanisms. Additionally, it functions as a research tool in hematology to investigate JAK-STAT signaling pathways and in drug discovery to explore novel targets in cancer therapy. According to "Janus Kinase Inhibitors: A Comprehensive Review," DS-1205b represents a promising candidate for modulating JAK2-mediated signaling in various disease contexts.
Reviews
Write Your Own Review